Therapeutic Cancer Vaccines

治疗性癌症疫苗

• 批准号: nhmrc : 264574
• 负责人: Prof Miles Prince
• 金额: $ 12.06万
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Strategic Awards
• 财政年份: 2004
• 资助国家: 澳大利亚
• 起止时间: 2004-01-01 至 2005-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/therapeutic-cancer-vaccines/77382
• 关键词: Therapeutic; Cancer; Vaccines

This project will develop and test a new cell-based anticancer vaccine for patients with Prostate cancer. The collaboration will involve French, Italian, Austrian and German researchers. Blood will be taken from patients in the clinical trial, the patient's cells will be converted into a cell vaccine, and these cells will be labelled with a radioactive tracer and re-injected into the host. Australian researchers at the Centre for Blood Cell Therapies at the Peter MacCallum Cancer Centre will then track the performance of the vaccine using advanced diagnostic imaging to determine how effective the vaccine is in stimulating the body's own defence mechanisms to fight the cancer. Multiple versions of the treatment are being developed by the international collaboration and the Institute will help determine which approach is most effective in combating cancer. The Peter MacCallum Cancer Centre is the foremost centre worldwide for this type of cell tracking study.

该项目将为前列腺癌患者开发和测试一种新的细胞抗癌疫苗。这项合作将涉及法国、意大利、奥地利和德国的研究人员。在临床试验中，将从患者身上抽取血液，患者的细胞将被转化为细胞疫苗，这些细胞将被标记有放射性示踪剂，并重新注射到宿主体内。Peter MacCallum癌症中心血细胞治疗中心的澳大利亚研究人员将使用先进的诊断成像技术跟踪疫苗的性能，以确定疫苗在刺激人体自身防御机制对抗癌症方面的有效性。国际合作正在开发多种版本的治疗方法，该研究所将帮助确定哪种方法在对抗癌症方面最有效。Peter MacCallum癌症中心是全球最重要的细胞追踪研究中心。